How do you fight leiomyosarcoma?

The primary approach for treating leiomyosarcomas involves surgical excision, encompassing the complete removal of the tumor and surrounding tissue through resection. Depending on the tumor’s location, surgical procedures may incorporate specific reconstructive techniques.


Opting for surgery stands as the optimal choice for treating LMS. Complete tumor removal offers a promising chance for curing LMS. However, if residual cancer cells persist, there is an increased risk of cancer recurrence, either at the original site or in other parts of the body.

Leiomyosarcoma treatment options?

The primary treatment for leiomyosarcoma involves surgery, with radiation therapy and chemotherapy frequently utilized alongside surgical intervention. Surgical procedures for leiomyosarcoma exhibit significant variability, contingent on factors such as tumor location and size. Jan 24, 2022

What constitutes the primary treatment for leiomyosarcoma?


Chemotherapy, a potent drug treatment, employs powerful chemicals to eradicate cancer cells. This approach may be advised if complete surgical removal of leiomyosarcoma is not feasible or if the cancer has metastasized to other regions of the body. Apr  27, 2023

First-line therapy for metastatic and/or unresectable leiomyosarcoma includes anthracycline or gemcitabine based regimens, which provide a median progression-free survival time of about 5 months and overall survival time between 14-16 months. Effective later-line therapies are limited. Mar 8, 2023

What constitutes the secondary treatment for leiomyosarcoma?


EU-approved as a second-line treatment, demonstrating efficacy in leiomyosarcomas, liposarcomas, myxoid liposarcomas, and potential clinical benefits in various histological types (Demetri 2015; Le Cesne 2005; Samuels 2013; Yovine 2004) as of October 12, 2016.

Utilizing Nomograms and Sarculator for Non-uterine and Uterine Leiomyosarcoma.

Our uterine leiomyosarcoma nomogram is a tool designed to predict the likelihood of survival at five years after undergoing surgery to remove the uterine leiomyosarcoma, a type of uterine cancer. It is not appropriate for patients who have not had surgical treatment for uterine leiomyosarcoma.

Results produced by this tool are based on data from patients treated at MSK, a large research institution with surgeons who perform a high volume of uterine cancer procedures. This tool has been externally validated using data from patients treated at large, international sarcoma centers (see Supporting Publications). All results must be understood in the context of each patient’s specific treatment plan. Patients and caregivers using this tool should discuss the result with the patient’s physician.

To gather the information required to use this nomogram, use our worksheet.


This application is tailored for medical professionals and is not intended for making clinical decisions, as the clinical efficacy of the two models is yet to be established. However, it serves as an informative tool to enhance physicians’ predictive capabilities.

There are two kinds of predictions:

  1. RPS: 7 years of global survival (GS) and 7 years of disease-free survival (DFS) on patients with retroperitoneal area primary resected 
  2. STS: global survival at 5 and 10 years and accumulated incidence of distant metastasis on patients with resected primary limb sarcoma.